News

Vertex Pharmaceuticals: Strong Growth and Strategic Advances
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Vertex (VERX) Q2 Earnings and Revenues Surpass Estimates
Vertex (VERX) delivered earnings and revenue surprises of +7.14% and +0.17%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Vertex’s Journavx successor culled after falling short in Phase II trial
Topline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.